TELA Bio, Inc. (TELA) is an innovative commercial-stage medical technology firm focused on the design, development, and marketing of a novel class of tissue reinforcement materials aimed at the $3 billion soft tissue reconstruction market. TELA Bio's products are used in essential surgical procedures in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
Based in Malvern, Pennsylvania, the company was founded in 2012 by a team of experienced healthcare and medical device professionals. TELA Bio's primary objective is to provide more cost-effective, biologically relevant options for surgeons and patients than the existing synthetic materials. Its mission is 'Restoring the Body's Natural Strength' and this is perfectly reflected in their major rank of products called 'OviTex Reinforced BioScaffolds'.
The OviTex products represent the first of a new category of surgical implants made from a unique blend of materials. They are the result of a sophisticated manufacturing process that seamlessly integrates polymer and biologic materials, providing unprecedented mechanical and biological properties that help surgeons restore the body's natural anatomy.
Furthermore, TELA Bio has launched a clinical study, 'Bravo', that showcases the safety and performance of OviTex - a study that is currently ongoing in multiple centers across the US. The Bravo study is expected to be one of the largest prospective, multicenter clinical studies in hernia repair with long-term follow-up of patients.
TELA Bio operates in a competitive landscape, but their innovative products have already shown wide acceptance in the medical community. The business model emphasizes working closely with surgeons to develop and commercialize its biologic products and surgical implants for hernia repair.
TELA Bio is a forward-thinking company, subject to stringent regulations encountered by all medical device manufacturers. Needless to say, their commitment is to meet and surpass these regulatory requirements.
The organization has a robust Intellectual Property (IP) portfolio, with a large number of patents and patent applications intended to protect its technology around the world. Its partnership with Aroa Biosurgery Limited, a soft tissue regeneration company, has allowed TELA Bio to access invaluable intellectual property and know-how in the field of tissue manipulation.
TELA Bio's vast market potential, clear product differentiation, and growing sales trajectory make it a notably unique player in the medical device industry. The company remains committed to revolutionizing soft tissue repair through biomaterial science, showing its dedication to improving outcomes for patients while reducing costs for healthcare systems.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
TELA Bio Inc. has received FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable synthetic surgical mesh. This marks the company's first in-house designed and produced synthetic product, expanding its soft-tissue reconstruction portfolio. The device was developed at TELA Bio's Malvern facility and provides surgeons with an additional option for tissue repair.
TELA Bio Inc. (TELA) has successfully regained compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Global Market. This resolution removes the risk of delisting, strengthening the company's market presence and potentially boosting investor confidence and access to capital markets. Despite this positive development for its listing status, Spark, TipRanks' AI Analyst, rates TELA as "Neutral" due to weak financial fundamentals, though technical indicators are somewhat positive.
TELA Bio, Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Global Market. The company received confirmation from The Nasdaq Stock Market LLC on October 5, 2026, indicating that the listing issue is now closed. TELA Bio's common stock will continue to trade on the Nasdaq Global Market under the ticker symbol "TELA."
TELA Bio, Inc. has received 510(k) clearance from the U.S. Food and Drug Administration for its Liora Monofilament Scaffold. This fully resorbable surgical mesh device will expand TELA Bio's presence in the soft tissue reconstruction market. Liora is the first fully resorbable synthetic product in TELA Bio's portfolio to be designed and produced in-house.